Log in to search using one of your social media accounts:

 

FDA Approves Opdivo for Hard-to-Treat Hodgkin Lymphoma

By Hope Cristol Patients with hard-to-treat Hodgkin lymphoma now have a new treatment option. The U.S. Food and Drug Administration granted accelerated approval to Opdivo (nivolumab) for classic Hodgkin lymphoma that has returned or progressed after a specific type of stem cell transplant and post-transplant medicine. Hodgkin lymphoma is a cancer of the lymph system, which is part of the immune system. There are two main types of this disease, but “classic” Hodgkin lymphoma accounts for about 95% of all cases in developed countries. The American Cancer Society estimates about 8,500 new cases of Hodgkin lymphoma will be diagnosed in 2016, with a 5-year survival rate ranging from 90% for stage I to 65% for stage IV. When Hodgkin lymphoma comes back after treatment (relapsed disease) or doesn’t go away after treatment (refractory disease), the next step is often an autologous stem cell transplant. This treatment uses high doses of chemotherapy, followed by reinfusing a patients’ own blood and marrow stem cells back into the body. The anticancer drug Adcetris (brentuximab vedotin) may be given to patients post-transplant. Opdivo, an immunotherapy drug, can now be used for Hodgkin lymphoma if these treatments don’t work. In clinical trials that formed the basis of the new approval, 95 patients with relapsed or refractory disease were treated with Opdivo. It was found to shrink tumors in 65% of patients: 58% achieved partial remission and 7% achie...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Hodgkin Disease Source Type: news

Related Links:

The thumbnail take on finasteride has been that it prevents prostate cancer but increases the risk for high-grade disease. A new study debunks the latter idea.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Smart technologies can sift through data to help the NHS spot diseases quicker, the PM is to say.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
LONDON (Reuters) - Prime Minister Theresa May will call on Britain's health service, charities and artificial intelligence sector to work together to better identify patients with the early stages of cancer and stop thousands dying each year.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This article will discuss those efforts and results to date. PMID: 29766832 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research
This study assessed the survival impact of combined surgery to the primary tumor and metastatic disease in the management of metastatic NSCLC. Stage IV NSCLC patients at presentation, diagnosed from 2004 to 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TN stage, and site of metastases). A total of 144,334 patients were identified. The median age group was 65-70 years, and 1139 patients (0.8% of the patients) have received surgical treatment to both the primary tumor...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
In conclusion, NSUN2 is a potential independent prognostic marker and may be a potential therapeutic target in HNSCC. PMID: 29775108 [PubMed - in process]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Authors: Kocaba V, Damour O, Auxenfans C, Burillon C Abstract In France, endothelial dysfunction represents approximately one half of the indications for corneal transplants performed each year. However, the use of endothelial keratoplasty is limited by the technical difficulty of the procedure, a shortage of available grafts, and the potential for graft failure or rejection. These limitations are driving researchers to develop new, less invasive, and more effective therapies. Corneal endothelial cell therapy is being explored as a potential therapeutic measure, to avoid the uncertainty associated with grafting. Th...
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
The costs associated with a cancer diagnosis can add to a patient's stress, which can have a negative effect on outcome. Nurses can help by being prepared to discuss the financial aspects of care.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nursing News Source Type: news
[The Conversation Africa] As cancer and other non-infectious diseases continue to rise all over the world it's become harder for scientists to find safe, effective treatments. In addition, bacteria are becoming more and more resistant to drugs and synthetic medicines have become harsher.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Abstract Hypoxia plays a crucial role in cancer progression, and it has great significance for monitoring hypoxic level in biosystems. Cancer stem cells (CSCs) represent a small population of tumour cells that regard as the key to seed tumours. The survival of CSCs depend on the tumour microenvironment, which is distinct region has the hypoxic property. Therefore, the detection of the hypoxic CSC niche plays a pivotal role in the destructing the 'soil' of CSCs, and eliminating CSCs population. Numerous one-photon excited fluorescent probes have been developed to indicate the hypoxic status in tumours through the d...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Food and Drug Administration (FDA) | Hodgkin's Disease | Immunotherapy | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Urology & Nephrology